Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal

It was a company that J&J didn't have success with, so they spun it off. It didn't work as a spin off, even with all of the activist investors circling around it. Why should its fate be any different with Kimberly-Clark.Yeah, that's a good question. I mean, this is this whole consumer health area is one where we've seen a huge amount of activity in recent years with a bunch of big pure play pharma companies like like Johnson and Johnson getting out of the air out of this area. We've seen it also with compan ...